The use of constitutively active receptors for drug discovery at the G protein-coupled receptor gene pool.
Several lines of evidence over the last decade have established that G protein-coupled receptors (GPCRs) can signal in the absence of their natural ligand which results in ligand-independent or constitutive activity. Natural genetic mutation, overexpression and site-directed mutagenesis all result in constitutive activation of GPCRs. Of the 100 leading pharmaceutical products in 2000, 39, wholly or in part, acted through a GPCR-mediated mechanism, a fact that underlines the extreme importance of GPCRs as pharmaceutical drug targets. In addition, the sequencing of the human genome and database mining has revealed that there are hundreds of putative orphan GPCRs for which the natural ligands have not been identified. These orphan GPCRs have largely been inaccessible to drug discovery because traditional methods have mainly relied on ligand-dependent binding assays to discover and pharmacologically characterize potential drug candidates from this receptor class. In the absence of ligand identification, constitutively active receptors allow for a logical and direct way forward through the drug discovery pathway by providing the tool necessary to find modulators of this receptor class in a ligand-independent fashion.
Behan
D P
DP
Arena Pharmaceuticals Inc., 6166 Nancy Ridge Drive, San Diego, CA 92131, USA. dbehan@arenapharm.com
Chalmers
D T
DT
D000818:Animals; D015195:Drug Design; D019204:GTP-Binding Proteins / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D009154:Mutation / Q000235:genetics; D010600:Pharmacology / Q000639:trends*; D011955:Receptors, Drug / Q000737:chemistry / Q000187:drug effects / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000737:chemistry; D015854:Up-Regulation / Q000187:drug effects
D011955:Receptors, Drug; D011993:Recombinant Fusion Proteins; D019204:GTP-Binding Proteins